Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 4, 2014 (13 years ago)

Azathioprine Tablets USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Incorrect or Missing Lot and/or Exp Date: This recall is being conducted because the product was given 36 month expiration dates instead of the filed 24 months.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Azathioprine Tablets USP, 50 mg, 100 count bottle, Rx only, Roxanne Laboratories, Inc., Columbus, Ohio, 43216, NDC 0054-4084-25

Affected NDC 0054-4084-25

Compare with the code on your package — it is the most precise check available.

Recalling firm
Boehringer Ingelheim Roxane Inc
NDC code
0054-4084-25
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1313-2014 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Boehringer Ingelheim Roxane Inc

All 2014 recalls
Class III · Low risk

FUROSEMIDE Tablets USP

CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.

Terminated cGMP deviation Boehringer Ingelheim Roxane Inc NDC 0054-4299-31 D-0012-2016
Class III · Low risk

FUROSEMIDE Tablets USP

CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.

Terminated cGMP deviation Boehringer Ingelheim Roxane Inc NDC 0054-4297-31 D-0011-2016
Class II · Moderate risk

Combivent Respimat

Defective Delivery System: Inhalers do not spray properly, emitting either no spray or a short transient spray.

Terminated Packaging defect Boehringer Ingelheim Roxane Inc NDC 0597-0024-02 D-1279-2015

Other labeling / mix-up recalls from 2014

All labeling / mix-up recalls
Class III · Low risk

3M ESPE Clinpro 5000

Labeling: Incorrect or Missing Lot and/or Exp. Date - The subject lot is missing the lot number and expiration date stamp on the primary box..

Terminated Labeling / mix-up 3M Company/3m Espe Dental Products NDC 48878-3130-04 D-0376-2015
Class II · Moderate risk

J-TAN D PD Drops

Labeling: Not Elsewhere Classified: Product is labeled "Dye Free" on front panel but contains Red Dye 40.

Terminated Labeling / mix-up Jaymac Pharmaceuticals L.L.C. D-0327-2015
Class III · Low risk

BELVIQ¿ (Lorcaserin HCl)

Labeling:Missing Label: Bottles may not have a product label, or have a label with missing or illegible lot number and/or expiry date.

Terminated Labeling / mix-up Eisai Inc D-0302-2015
Class III · Low risk

Fluoxetine Capsules USP

Labeling: Illegible Label: Sandoz Inc. is recalling of one lot of Fluoxetine Capsules due to an illegible logo on the capsule.

Terminated Labeling / mix-up Sandoz Incorporated NDC 0781-2822-01 D-0291-2015